Existing investors Amgen and Astellas participated in a round that lifted the immuno-oncology treatment developer's total financing to $70m.
US-based immuno-oncology company Tizona Therapeutics completed a $43m series B round today that included corporate venturing subsidiaries of pharmaceutical companies Amgen and Astellas.
Amgen Ventures and Astellas Venture Management were joined by Abingworth and Canaan Partners, which co-led the round, Lightstone Ventures, MPM Capital and InterWest Partners.
Founded by MPM Capital, Tizona is working on treatments that would activate the body’s immune system to fight cancer, or prevent it from attacking healthy tissues in autoimmune diseases.
The company’s lead…
